pulmonologyadvisor11d
Switching Biologics Occurs in 16% of Patients With Asthma, for Various Reasons
Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...
biopharma-reporter14d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
GlobalData on MSN14d
EC approves AstraZeneca’s Fasenra for EGPA treatment
Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
PharmiWeb15d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Frontiers19d
Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
This study aimed to investigate the safety of mepolizumab by analyzing the pharmacovigilance database of the US Food and Drug Administration. Methods: The AE signals associated with mepolizumab from ...
EuropaWire29d
GSK Reports Promising Phase III Findings for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps
(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...